Product
HybriMore™ Hybridoma Culture Supplement
Highlights:
- Increase cloning efficiency and cell survival rate
- Growth promoting supplement with defined chemical component and concentration
- Better signal-to-noise ratio of hybridoma supernatant for mAb screening
Order Information:
Cat. No. | Product Name | Description |
HB01-1L | HybriMore™ Hybridoma Culture Supplement* |
For 1 L culture medium dilution |
*Previous name: HybriMore Hybridoma Cloning Factor
Product Detail:
Figure 1. Comparison of the cloning efficiency of the newly fused hybridoma cells.
The newly PEG fused hybridoma cells were plated into a 96-well plate containing FCS media with HybriMore™ (green bars), FCS media with feeder layer (blue bars), or regular FCS media (white bars). Hybridoma cells were subject to HAT selection 14 days after cell fusion. The numbers of viable hybridoma colonies were visually counted under a microscope. Two mouse myeloma fusion partners, NS-1 and SP2/0, were evaluated by four independent fusion experiments with freshly prepared mouse spleens.
Figure 2. Comparison of the successful rate of monoclonizing hybridoma cells.
Eight clones of hybridoma cells from NS-1 or SP2/0 fusion partners were monoclonized in the media containing FCS media with HybriMore™ (green bars), FCS media with feeder layer (blue bars), or regular FCS media (white bars). The numbers of viable hybridoma colonies in a well were visually counted under a microscope.
Figure 3. Comparison of the titers of secreting Ab.
A clone of hybridoma cells (anti human transferrin, L3B5) was cultured in the media containing FCS media with HybriMore (green bars), FCS media with feeder layer (blue bars), or regular FCS media (white bars) for seven days. The supernatants were harvest and examined by the titer of secreting Ab by ELSIA assay.
Reference:
1. Li, CJ., Huang, PH., Chen, HW. et al. Development and characterization of mouse monoclonal antibodies targeting to distinct epitopes of Zika virus envelope protein for specific detection of Zika virus. Appl Microbiol Biotechnol (2021).
2. Lai, Guan-Chun, et al. "Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain." Antiviral Research 200 (2022): 105290.